LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01860118|
Recruitment Status : Completed
First Posted : May 22, 2013
Last Update Posted : May 11, 2018
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||601 participants|
|Official Title:||LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||June 21, 2016|
|Actual Study Completion Date :||June 21, 2016|
1) the presence of bradykinesia and either rest tremor or rigidity; 2) asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years.
Healthy controls between ages of 21-99 years and a lack of PD in first-degree blood relatives
- Biomarkers [ Time Frame: up to 3 years ]Biomarkers associated with Parkinson's disease (PD) susceptibility and/or progression in exosome-proteomes derived from PD patients versus controls.
- LRRK2 expression and/or phosphorylation [ Time Frame: up to 3 years ]Determine if LRRK2 expression and/or phosphorylation are significantly lowered in the exosomes of individuals treated with the potent LRRK2 kinase inhibitor sunitinib (a multi-kinase inhibitor compound), to establish an assay for on-target effects for future LRRK2 inhibitor clinical trials.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01860118
|United States, Alabama|
|University of Alabama at Birmingham Sparks Center|
|Birmingham, Alabama, United States, 35294|
|Principal Investigator:||Andrew West, PhD||University of Alabama at Birmingham|